Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes

• Status: Active, not recruiting
• Trial end date: 2022-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aimed to compare efficacy and safety of IGlarLixi and insulin glargine plus dulaglutide as intensification from basal insulin with metformin, in the absence of head-to-head trials.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chungbuk National University Hospital
• Treatments: Dulaglutide; Insulin Glargine

Criteria

Inclusion Criteria:

• Age ≥ 18 years old

• Patient with type 2 diabetes, treated with basal insulin plus metformin (maximum tolerated dosage) for at least 12 weeks

• Patient accepting to participant to this study

Exclusion Criteria:

• Pregnant or breastfeeding woman

• severe renal dysfunction (eGFR <60 ml/min/1.73m2)

• chronic or acute hepatic disorder (HBV or HCV hepatitis, liver cirrhosis etc.) (AST/ALT > 2.5*ULN)

• Prescription such as immunosuppressant agents, glucocorticoids

• Active anti-cancer treatment